We are here to assist you.
Health Advisor
+91-8877772277Available 7 days a week
10:00 AM – 6:00 PM to support you with urgent concerns and guide you toward the right care.
Join our healthcare community
Understand the impact of Omvoh (mirikizumab) on reproductive health, including considerations for pregnancy, breastfeeding, and fertility in patients with ulcerative colitis. Get essential information for informed discussions with your healthcare team.
Living with ulcerative colitis (UC) involves managing chronic inflammation and finding effective treatments to improve your quality of life. Omvoh (mirikizumab) is a biologic medication approved for adults with moderately to severely active UC. While Omvoh can be highly effective in managing symptoms, it's natural to have questions about how any long-term medication might affect other aspects of your health, especially reproductive health. For individuals planning a family, those who are pregnant, or breastfeeding, understanding the potential impact of Omvoh is crucial. This comprehensive guide will explore what is currently known about Omvoh and its considerations for reproductive health, empowering you to have informed discussions with your healthcare team.
Omvoh (mirikizumab) is a targeted biologic therapy that works by selectively binding to the p19 subunit of interleukin-23 (IL-23), a cytokine involved in inflammatory and immune responses. By blocking IL-23, Omvoh helps to reduce inflammation in the gut, thereby alleviating symptoms and promoting mucosal healing in patients with ulcerative colitis. It is administered as an intravenous (IV) infusion for induction and then as subcutaneous injections for maintenance.
Before delving into Omvoh specifically, it's important to understand that ulcerative colitis itself can influence reproductive health. Active UC inflammation can sometimes be associated with reduced fertility in both men and women, although many individuals with UC conceive without difficulty. During pregnancy, active UC can lead to adverse outcomes such as preterm birth, low birth weight, and increased risk of complications for both mother and baby. Therefore, achieving disease remission before conception and maintaining it throughout pregnancy is often a primary goal, and medication management plays a vital role in this.
Current data on the use of Omvoh during human pregnancy is limited, as is often the case with newer medications. Most of our understanding comes from animal reproduction studies and a growing body of real-world experience, although comprehensive human studies are ongoing or still accumulating.
In animal studies, mirikizumab did not show evidence of direct harm to the fetus or reproductive capacity at doses relevant to human exposure. However, animal studies do not always perfectly predict human responses.
As a monoclonal antibody, Omvoh is an IgG4 antibody. IgG antibodies are known to cross the placenta, especially during the second and third trimesters. This means that an unborn baby will be exposed to the medication. The potential effects of this exposure on the developing immune system of the infant are not fully understood, but generally, live vaccines are often avoided in infants exposed to biologics in utero until their immune systems have matured. Healthcare providers typically weigh the potential benefits of continuing Omvoh treatment for the mother's UC against any potential risks to the fetus. Uncontrolled UC during pregnancy poses significant risks to both mother and baby, sometimes outweighing the theoretical risks of continuing a medication like Omvoh.
If you are pregnant or planning to become pregnant while on Omvoh, it is paramount to have an open and detailed discussion with your gastroenterologist and obstetrician. They will help you evaluate:
Some women may be advised to continue Omvoh throughout pregnancy, especially if their disease is active or severe, to prevent flares that could be more detrimental. Others might be advised to adjust their treatment plan. Never stop or change your medication without consulting your healthcare provider.
The presence of Omvoh in human milk, its effects on the breastfed infant, or its effects on milk production are currently unknown. However, like other large protein molecules (monoclonal antibodies), mirikizumab is expected to be present in breast milk at very low levels, if at all, due to its size, which typically limits transfer into milk. Furthermore, if ingested by an infant, it is likely to be largely broken down in the infant's gastrointestinal tract and poorly absorbed into their bloodstream.
Given the limited data, healthcare providers will typically consider the mother's clinical need for Omvoh, the potential risks to the infant, and the benefits of breastfeeding. The general consensus for many biologics is that the risk to a full-term, healthy infant is often considered low due to poor oral bioavailability and limited transfer. However, discussions with your doctor are essential to make an informed decision that prioritizes both your health and your baby's well-being.
Currently, there is no specific evidence to suggest that Omvoh (mirikizumab) negatively impacts male fertility or sperm quality. Most research on biologics and reproductive health focuses on female patients due to the direct involvement of pregnancy and breastfeeding. However, maintaining good control of ulcerative colitis can positively impact male fertility, as chronic inflammation and poor health can affect sperm production and function. If you are a male patient on Omvoh and have concerns about fertility, discuss these with your gastroenterologist or a fertility specialist.
Due to the limited data on Omvoh during pregnancy, it is generally recommended that women of reproductive potential use effective contraception during treatment with Omvoh and for at least 10 weeks after the last dose. This recommendation accounts for the drug's half-life and ensures that the medication has sufficiently cleared from the system before conception. Always discuss your contraception needs and options with your healthcare provider.
It is crucial to maintain open communication with your healthcare team at all stages of your reproductive journey while on Omvoh:
Based on animal studies, Omvoh has not been shown to cause birth defects. However, human data is limited. The decision to use Omvoh during pregnancy involves carefully weighing the risks of uncontrolled UC against the theoretical risks of medication exposure, in consultation with your healthcare provider.
Not necessarily. The decision to stop or continue Omvoh is highly individualized. Stopping treatment could lead to a UC flare, which can be more harmful to a pregnancy than continuing the medication. Discuss your family planning goals with your doctor to make the best decision for your health and future pregnancy.
It is generally recommended to use effective contraception during treatment and for at least 10 weeks after the last dose of Omvoh to ensure the medication has cleared from your system. Always follow your doctor's specific advice.
Monoclonal antibodies like Omvoh can cross the placenta, especially in later pregnancy. This exposure might affect the baby's immune response, particularly concerning live vaccines. Your pediatrician will be informed about your medication use during pregnancy to guide your baby's vaccination schedule.
There is no current evidence to suggest that Omvoh negatively impacts male fertility. Maintaining well-controlled UC can actually support overall health, including reproductive health.
Navigating treatment for ulcerative colitis while planning a family or during pregnancy and breastfeeding requires careful consideration and expert guidance. Omvoh (mirikizumab) offers an effective treatment option for many, but its use in reproductive contexts needs thorough discussion with your healthcare team. While human data is still accumulating, current understanding suggests a cautious approach, emphasizing shared decision-making. Always prioritize open communication with your gastroenterologist, obstetrician, and pediatrician to ensure the best possible outcomes for both you and your family.
The information provided in this article is intended for general knowledge and informational purposes only, and does not constitute medical advice. For specific medical advice, diagnosis, and treatment, always consult with a qualified healthcare professional. This article is based on general medical understanding of biologics, current drug information, and common clinical practices. Always refer to the official prescribing information for Omvoh (mirikizumab) and consult your doctor for personalized guidance.
Visit Hospital
Near You
Learn about kidney transplant options in Narendrapur, recovery, and donor criteria. Expert insights for informed decisions.
May 19, 2026
Explore LASIK eye surgery in Madhepura. Learn about eligibility, the procedure, benefits, risks, and costs from trusted specialists.
May 19, 2026
Explore LASIK surgery in Nalanda. Understand eligibility, the procedure, recovery, and costs for vision correction at leading eye clinics.
May 19, 2026